Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
AIDS Rev. Author manuscript; available in PMC 2009 October 1.
Published in final edited form as:
PMCID: PMC2666328

HTLV-1 Yin and Yang: Rex and p30 Master Regulators of Viral mRNA Trafficking


Human retroviruses are associated with a variety of malignancies including Kaposi’s sarcoma and Epstein-Barr virus-associated lymphoma in HIV infection, T-cell leukemia/lymphoma and a neurologic disorder in human T-cell lymphotropic virus type 1 (HTLV-1) infection. Both HIV and human T-cell lymphotropic virus type 1 have evolved a complex genetic organization for optimal use of their limited genome and production of all necessary structural and regulatory proteins. Use of alternative splicing is essential for balanced expression of multiple viral regulators from one genomic polycistronic RNA. In addition, nuclear export of incompletely spliced RNA is required for production of structural and enzymatic proteins and virus particles. Decisions controlling these events are largely guarded by viral proteins. In human T-cell lymphotropic virus type 1, Rex and p30 are both nuclear/nucleolar RNA binding regulatory proteins. Rex interacts with a Rex-responsive element to stimulate nuclear export of incompletely spliced RNA and increase production of virus particles. In contrast, human T-cell lymphotropic virus type 1 p30 is involved in the nuclear retention of the tax/rex mRNA leading to inhibition of virus expression and establishment of viral latency. How these two proteins, with apparently opposite functions, orchestrate virus replication and ensure vigilant control of viral gene expression is discussed.

Keywords: HTLV-1, Rex. p30, RNA export, Posttranscriptional regulation


In 1977, epidemiologic studies revealed the presence of unusual clusters of adult T-cell leukemia/lymphoma (ATLL) in contained areas of Japan, suggesting that a transmissible agent may be involved in the disease1. The first description of the virus was made after the discovery of the human T-cell growth factor (interleukin-2; IL-2), allowing long-term in vitro culture of Tcells and establishment of T-cell lines from a patient with a cutaneous T-cell lymphoma2,3. A retrovirus was identified as the etiologic agent of ATLL and the terminology human T-cell lymphotropic virus type 1 (HTLV-1) was adopted4. Adult T-cell leukemia/lymphoma is an aggressive and fatal malignancy of CD4+ T lymphocytes. The overall survival with various chemotherapy regimens is poor, ranging between 5.5 and 13 months in several cohorts of patients presenting predominantly with acute leukemia or lymphoma5. The HTLV-1 infection is also associated with a chronic and progressive neurologic disorder named HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)6,7 as well as other malignancies such as HTLV-1-associated arthropathy, HTLV-1-associated uveitis, infective dermatitis, and polymyositis8.

The low incidence and the long latency of HTLV-1-associated ATLL suggest that, in addition to viral infection, accumulation of genetic defects is required for cellular transformation in vivo. The HTLV-1-mediated T-cell transformation presumably arises from a multistep oncogenic process in which the virus induces chronic T-cell proliferation, resulting in the accumulation of genetic defects, deregulated growth, and expanded lifespan of infected cells9. Profound differences exist in the pathogenesis of ATLL and HAM/TSP. The ATLL is characterized by a monoclonal expansion of virus-infected cells. The virus is latent and viral gene expression is barely detectable, with both the cytotoxic T-lymphocyte (CTL) and antibody immune responses against the viral antigens being poor. In contrast, in HAM/TSP, expression of viral genes is higher, leading to de novo infection and polyclonal expansion of infected cells. In these patients, a strong CTL and antibody response is present, causing a constant killing of infected cells, which is balanced by de novo infection10,11. The determinants that lead to the development of ATLL versus HAM/TSP are unclear.

The genome of HTLV-1 encodes common structural and enzymatic proteins found in retroviruses (Gag, Pro, Pol, and Env). In addition, as a complex retrovirus, HTLV-1 encodes multiple regulatory and accessory proteins in four overlapping open reading frames located in the pX region of the viral genome12,13 (Fig. 1). Expression of the various open reading frames is controlled by differential splicing of the single genomic mRNA, producing unspliced, singly spliced, and multiply spliced mRNA15. Therefore, the replication of HTLV-1 is controlled by a group of nuclear and cytoplasmic processes, including transcription, splicing, mRNA nuclear export, RNA stability, and translation. In addition, recent studies suggest the existence of viral encoded RNA from the 3′ long terminal repeat (HBZ)17, which are also subject to alternative splicing and generate additional viral proteins.

Figure 1
Expression of HTLV-1 proviral genome. The genome of HTLV-1 encodes common structural and enzymatic proteins found in retroviruses (Gag, Pro, Pol and Env) and multiple regulatory and accessory proteins. Expression of HTLV-1 proviral genome is regulated ...

The HTLV-1 gene expression is self-regulatory, determined by the expression of two viral-encoded regulatory genes that act in trans at the transcriptional (tax) or posttranscriptional level (rex). Virus expression is controlled by the 5′ long terminal repeat (LTR). While the HTLV-1 LTR can be activated by numerous cellular factors, potent activation is achieved after recruitment of the viral Tax protein, which brings together the cellular factor, CREB, and the transcriptional co-activators, CBP/p300 and PCAF, to the transcription machinery1823. Tax is a relatively small protein with a remarkable number of distinct functions, including cellular proliferation, inhibition of apoptosis, genetic instability, telomerase activation, and inactivation of tumor suppressors2428. Tax is expressed from the tax/rex RNA which also encodes for the Rex protein. Thus, in contrast to the Tat and Rev proteins of HIV, HTLV-1 Tax and Rex are coregulated and expressed from the same RNA.

HTLV-1 Rex: a positive posttranscriptional regulator

RNA nuclear export adaptor

Cellular RNA processing leads to rapid splicing of intronic sequences or their eventual destruction, which contrasts with the need for unspliced and partially spliced mRNA required for HTLV-1 replication. The HTLV-1 and other related virus (HIV) have evolved a molecular mechanism in which viral adaptors (Rex for HTLV-1 and Rev for HIV-1) are recruited to a specific cis-regulatory RNA sequence. Several studies have demonstrated that Rex can interfere with the cellular splicing machinery and lead to cytoplasmic accumulation of unspliced genomic RNA encoding for GAG, PRO, POL, and singly spliced RNA encoding for Env (Fig. 2)29. Therefore, once the viral adaptors are recruited onto the viral RNA, they inhibit the recruitment of retention and splicing Factors and export the RNA to the cytoplasm as mature RNA. In general, proteins cargos are transported through the nuclear membrane by a set of cellular receptors known as exportins and importins that recognize specific sequence in their proteins cargos. Proteins only having a nuclear localization signal (NLS) are selectively imported into the nucleus. However, proteins having an NLS and NES (nuclear export signal) are recognized by both receptors and then shuttles between nucleus and cytoplasm. Similar to HIV Rev30, HTLV Rex has evolved a NES, which, with its NLS, allows shuttling between the nucleus and cytoplasm and stimulates the nucleocytoplasmic export of not fully spliced viral RNA through recruitment of chromosome maintenance region 1 (CRM1)/(or Exportin1) (Fig. 2). The NES domain, known as the Rex-activation domain, is a short, amino acid sequence (LSAQLYSSLSLD), highly hydrophobic, with leucine residues interspersed with hydrophilic residues31. The activation domain of Rex was shown to complement a defective effector domain mutant of Rev and was dependent on the hydrophobic nature of the leucine residues32. Mutations of the four leucine residues within the Rex-activation domain demonstrate that they are critical for nuclear export of mRNA and this interaction requires a hydrophobic region32,33. A core tetramer sequence (LXLX), along with two upstream hydrophobic residues (in the case of Rex and Rev, two essential leucines), compose the Rex NES32. Human CRM1 is an export receptor for leucine-rich NES and was initially found to be a receptor for the Rev NES3436. The CRM1 uses guanosine diphosphate/guanosine triphosphate (GDP/GTP) guanine nucleotide exchange of the GTPase Ran to function. The CRM1 binds to RanGTP, along with a NEScontaining protein, and translocates this complex across the nuclear pore where RanGTP is then converted to RanGDP. The regulator of chromosome condensation 1 (RCC1) catalyzes the GTP to GDP conversion37. Rex was also shown to bind to the CRM1 receptor in cooperation with RanGTP and RanBP3, a scaffold protein that aids in the formation of the protein-export complex, in addition to binding to RCC1 to promote more efficient Ran nucleotide exchange38,39. RanBP3 was shown to stabilize the RanGTP-CRM1-RanBP3- NES complex in the nucleus.

Figure 2
Control of viral mRNA trafficking by Rex and p30. Unspliced and singly spliced mRNA are exported to the cytoplasm by the Rex-CRM1 nuclear export pathway. The doubly spliced tax/rex mRNA is retained in the nucleus by p30. RXRE; Rex responsive element; ...

Several studies have also demonstrated that the formation of Rex-Rex multimers on the Rex target sequence is critical for HTLV-1 nuclear export of mRNA. Other Studies with HIV Rev demonstrated that multiple copies of Rev were required to bind to the Rev responsive element (RRE) in order to accumulate cytoplasmic HIV mRNA40. Furthermore, mutations of Rex and Rev that failed to form multimers act as dominant-negative mutants, suggesting that multimerization is critical for the functions of these proteins41. Although multimerization was found to be critical for Rex function, Rex Mutants defective for multimerization retained their ability to shuttle in and out of the nucleus42. The importance of Rex multimerization was highlighted using an in vivo rat model. In fact, HTLV-1 infection of rats produces high levels of tax/rex mRNA, but fails to produce significant expression of Gag and Env proteins43. In these models, the activity of Rex has been found to be quite low compared to that in human cells and this failure was due to the rat CRM1. Unlike human CRM1, rat CRM1 could hardly support Rex function because of its poor ability to induce Rex-Rex multimerization44. However, establishment of a transgenic rat with human CRM1 produced 100–1,000-fold more HTLV-1 than did T-cells derived from wild-type rats45. In addition to functioning as a Rex exporter, CRM1 serves as an inducing factor for Rex multimerization on mRNA by aiding in the complex formation required for HTLV-1 mRNA export39,46. Residues 411 and 414 of CRM1 were critical for Rex (but not Rev) multimerization, a region distinct from the role of CRM1 in the export of Rex. These two domains (along with residues 474 and 481) overlap with the region required for efficient binding of CRM1 to the scaffold protein RanBP3, suggesting that the multimerization of Rex and the interaction with RanBP3-CRM1 are linked46. Collectively, the requirement for multiple bound copies of Rex on the mRNA is believed to protect HTLV-1 mRNA from being bound by proteins that could induce cellular splicing or nuclear retention. An increased number of Rex proteins would also facilitate binding of a larger number of CRM1 proteins, allowing for more efficient nuclear export. Studies have also shown that translation-initiation factor eIF-5A may play a part in the formation of the Rex homo-oligomers47.

RNA binding protein

Rex is known to be a nuclear/nucleolar phosphoprotein acting at the posttranscriptional level (Fig. 3A). In addition to the activation domain, Rex function is mediated through direct interaction with a cis-acting RNA element termed the Rex-responsive element (RXRE)48, present in the 3′ LTR (Fig. 3B). The RXRE forms a distinct stem-loop structure that is orientation dependent, but position independent, and is separate from 3′-mRNA processing and polyadenylation49. Rex function requires this large stem-loop and a 10-nucleotide subregion within the RXRE of viral transcripts, which directly interacts with the Rex protein5052. Rex shares many features with its homolog HIV Rev. While Rex and Rev have very little sequence homology, they both are functionally and structurally similar. In fact, Rex and Rev both have an arginine-rich region that is responsible for binding to their respective response elements; however, only Rex can functionally substitute for Rev51,5355 using a Rev-deficient HIV-1 provirus55. Rex can bind to both responsive elements, whereas Rev is unable to recognize the RXRE54. The minimum continuous regions within the RRE that are required for Rex and Rev functions differ between the two proteins, with Rex requiring a longer region of the RRE to bind (289 nt to 204 nt)56. Rex also has a higher affinity for RXRE than RRE, and regulates viral mRNA expression to a much higher extent with the RXRE. In contrast to the interaction between Rev and its responsive element, Rex’s interaction with its RXRE has also been found to be inhibited by the cellular protein, heterogeneous nuclear ribonucleoprotein A157. Another difference between Rex and Rev is that in HIV, the RRE is only found in unspliced or incompletely spliced HIV-encoded mRNA. However, all HTLV-1 mRNA carry the RXRE at their 3′ end. While the reason for this remains unclear, one possible explanation is that Rex binding to the RXRE stabilizes a complex secondary structure that bridges the poly-A signal and the poly-A site together since these are unusually far apart in the HTLV-1 genome (Fig. 3B). In fact, it has been proposed that the RXRE plays a role in the polyadenylation of HTLV-1 transcripts58. The structure of the stem-loop allows the AAUAAA hexamer and GU-rich elements to come into close contact, which then serves as a signal for polyadenylation. The Rex NLS59 binds to the nucleolar shuttling protein B-23, importing Rex into the nucleolus60. Mutations of the arginine residues contained in this domain prevent Rex from nuclear accumulation and from binding to RXRE sequences54. Interestingly, the arginine-rich region has recently been found to be involved in Rex-p30 interactions61.

Figure 3
Rex and p30 functional domains and structures. Mapping of Rex (A) and p30 (C) functional domains and their respective target sequences (B) and (D): the RXRE RNA responsive element; p30 specific responsive element p30RE. LTR: long terminal repeat; RXRE; ...

In addition to its role in RNA trafficking, Rex has been shown to increase mRNA stability and/or enhance the translation of incompletely spliced mRNA, but the exact mechanism(s) underlying this activity is still not understood62. Rex activities have been shown to be regulated by phosphorylation since treatment of an HTLV-1 infected cell line with a protein kinase inhibitor blocked the cytoplasmic accumulation of unspliced gag-pol mRNA63. Phosphorylation of serine 70 in Rex appeared to be dependent on cellular protein kinase C64. Rex was also found to be phosphorylated on serine 177 and threonine 174. The exact role of Rex phosphorylation still remains to be determined. In addition to Rex’s role in regulating viral gene expression, Rex has been shown to affect cellular gene expression. Rex was able to augment Tax-mediated increases in IL-2 expression and stabilize the IL-2 receptor-alpha chain (IL-2Rα) mRNA65,66. Rex was able to prolong the half-life of IL-2Rα mRNA, independent of nuclear-cytoplasmic transport66. The N-terminal, basic amino acid portion of Rex, encoding the NLS signal, was found to stabilize the 201–300 base pair region in the 5′-coding region of the IL-2Rα mRNA67,68. In this manner, Rex may contribute to cellular transformation of HTLV-1 infected cells. Rex has also been shown to increase FynB (p59fyn) expression, possibly by affecting FynB splicing69. FynB is a src family protein-tyrosine kinase that regulates T-cell receptor stimulation70. Co-transfection experiments in Jurkat T-cells demonstrated that Rex could augment Tax in increasing vascular cell adhesion molecule-1 (VCAM-1) and lymphocyte function-associated antigen-3 (LFA-3) expression71. Both VCAM-1 and LFA-3 are important proteins in T-cell adhesion, aiding in proliferation of uninfected cells and virus spread.

Although considerable knowledge about the role of Rex in virus replication has been gained, important questions still remain as to how Rex is able to regulate some viral mRNA but not others since all HTLV-1 transcripts contain an RXRE sequence. If both Tax and Rex act as positive regulators of viral gene expression, how is the virus able to reduce its expression and evade immune defenses? Answers to these questions came in 2004 when a negative viral posttranscriptional regulator was described. The study demonstrated that p30 binds to and subsequently retains the tax/rex message in the nucleus, preventing production of viral structural proteins by Tax and Rex72.

HTLV-1 p30: a negative posttranscriptional regulator

In the last decade several investigators have started to uncover the functions of additional HTLV-1 accessory proteins encoded by the pX region (p12, p13, and p30)7375. Although it has been proposed that most of these proteins are dispensable for in vitro human T-cell immortalization67,76,77, in our experience such cell lines have multiple growth defects in vitro. Nonetheless, several aspects about these small regulatory proteins are irrefutable. They are all expressed in vitro and RNA can be detected in HTLV-1 transformed T-cell lines7880. They are also expressed in vivo since both cell-mediated and antibody immune responses directed against these proteins have been detected in infected patients81,82. These regulatory proteins play critical roles for in vivo infectivity in a rabbit model8387. Of note, these genes are located in the originally called “nonconserved” region of the HTLV-1 genome, which has the highest genetic variability among isolates. Although isolates with stop codons in these genes have been found in infected patients, it does not mean that these genes were originally mutated during initial infection and/or the early stages of disease. These genes may have already accomplished their functions prior to being mutated. In fact, isolates with a stop codon in the tax open reading frame have been reported. Recent reviews have described in detail the functions of the p12 and p13 proteins73,74. The p30 protein is intriguing because it is reported to act as both a transcriptional and posttranscriptional regulator, a characteristic shared by another nucleolar resident protein, nucleolin. The p30 has similarities with serine-rich proteins, including several transcriptional activators such as oct-1, oct-2, pit-1, engrailed, and POU-Mi transcription factors13. Transient transfection experiments confirmed the transcriptional activity of p30 in Gal4 experiments. In addition, DNA microarray studies also showed that p30 was able to modify the expression profile of key cellular genes involved in leukemogenesis88. The transcriptional activities of p30 have been reviewed73,74. This review focuses on the posttranscriptional activity of p30 and the interplay with Rex.

The p30 RNA response element (p30RE) is responsible for the formation of the ribonucleoprotein complex and the retention of the tax/rex RNA in the nucleus, reducing Tax and Rex protein expression and promoting latency72 (Fig. 2). Similar results were subsequently obtained using p28, a p30 homolog, in HTLV-289. This is a unique example of negative regulation among viruses. Although the exact sequence required for p30-mediated retention has not yet been defined, earlier studies have shown that the p30RE encompass the envelope exon junction since the tax/rex but not the viral RNA is regulated by p30 (Fig. 3D)72. The p30 contains a sequence with homology to a NES, but heterokaryon assays demonstrated that, unlike Rex, p30 is a non-shuttling protein72. In addition, p30 does not interact with CRM1 and a mutation, which restores the consensus NES sequence (Ser to Leu), does not provide shuttling capability to p30 (unpublished data).

The nucleolus is not membrane bound and its structure is maintained by an accumulation of ribosomal RNA and proteins such as nucleolin or protein B23. Most proteins are only transiently retained in the nucleolus through protein or RNA interactions, and proteins with longer resident times usually harbor specific signals90. These signals tend to be nucleolar retention signals, generally characterized by sequences rich in arginine and lysine91,92. In vivo kinetics of p30 fused to a green fluorescent protein (GFP-p30) in the nuclear and nucleolar compartments, analyzed by live cell imaging, indicated that p30 is highly mobile in the nucleus but very static in the nucleolus93. In cells expressing GFP-p30, only a small fraction of the fluorescence signal was lost within the first five seconds after a bleaching event, followed by a slower decline of the nucleolar signal. Surprisingly, the kinetics of GFP-p30 are very similar to nucleolar methyltransferase fibrillarin-GFP, suggesting that p30 is tightly bound to nucleolar components93. The nucleolar retention signal of p30 was identified as an unusually short Arg-rich stretch, RRCRSR, (Fig. 3C) and deletion of this sequence or replacement of all Arg’s into Ala’s prevents accumulation of p30 in the nucleolus93. Single substitution of any Arg had no effect on nucleolar localization. In the same study, localization of various truncated forms of p30 revealed the presence of four NLS domains in p30 (Fig. 3C).

The nucleolus is critically involved in the control of the cell cycle, DNA repair, aging, and mRNA export94. Many viruses encode for nucleolar proteins, which are involved in the replication of viral genomes, as well as in the transcriptional and posttranscriptional regulation of gene expression95,96. The use of mutants of p30 unable to accumulate into the nucleolus indicated that nucleolar localization of p30 is dispensable for its transcriptional and posttranscriptional effects93. Nucleoli are mainly the sites of ribosome biogenesis, a highly complex process leading to the production of pre-ribosomal particles, which are then released into the nucleoplasm and exported to the cytoplasm as mature ribosomal subunits. Confocal microscopy indicated that a GFP-p30 fusion protein localized to the granular center93, which is the site of pre-ribosome assembly. Interestingly, p30 was also found to interact with L18a, a constituent of the 60S ribosomal subunit93. While the biological significance of this interaction is unclear, it is worth noting that L18a interacts with viral proteins and with initiation factor eIF3 and facilitates internal re-initiation of translation in Cauliflower mosaic virus- and Hepatitis C virus-infected cells97101. The p30 encoding mRNA completely overlaps two other viral gene’s open reading frames, namely p12 and p13. Whether p30 expression may directly or indirectly modulate internal initiation to increase expression of these genes warrants further studies.

The accumulation of several proteins in the nucleoli including Rex and Rev is transcription-dependent102,103. Measurement of GFP-p30 recovery kinetics in response to actinomycin D treatment by fluorescence recovery after photo-bleaching indicated a much slower recovery of fluorescence following actinomycin D treatment93. This confirms that GFP-p30 is in fact retained in the nucleoli in a transcription-dependent manner via interaction with less-mobile nucleolar components. This was supported by the calculated T1/2 recovery for the wild-type GFP-p30 (approximately 9 seconds) compared to GFP-p30 in cells treated with actinomycin D (77 seconds). These results indicate that p30 retention is associated with RNA polymerase II- and RNA polymerase III-dependent transcription of nascent RNA93.

The p30-mediated repression of tax/rex RNA export does not depend upon the splicing machinery, since cDNA from the tax/rex sequence remained sensitive to p30 inhibition72 and p30 was found to interact with the spliced tax/rex mRNA in transfected cells72,89. Since the p30RE is not present in viral RNA until the env exon has been spliced out, it is likely that p30 interacts only with fully spliced, mature tax/rex nuclear transcripts.

Rex and p30 interactions control the fate of viral RNA and govern the switch between virus latency and replication

Both HTLV-1 Rex and p30 are RNA binding regulatory proteins. Rex interacts with the RXRE and stimulates nuclear export of incompletely spliced viral RNA, thereby increasing production of virus particles. In contrast, p30 is involved in the nuclear retention of the tax/rex mRNA leading to inhibition of virus expression and establishment of viral latency. How these two proteins, with apparently opposite functions, integrate in the viral replication cycle is unclear. Recent studies shed light onto how these two proteins modulate each other’s function. Using recombinant protein and transient transfection assays, p30 was found to specifically form complexes with Rex in vivo and in vitro61. A region located between amino acids 131–164 of p30 encompasses the Rex binding site (Fig. 3C), a region not present in the p13 protein, which expectedly did not bind Rex. Mutants of p30 that localized in the nucleus or the nucleolus were both able to interact with Rex, suggesting that these proteins form complexes in the nucleoplasm. Interactions between Rex and p30 were strengthened when co-expressed in the presence of an HTLV-1 molecular clone but not in presence of Tax, suggesting that p30-Rex complexes are stabilized onto viral mRNA61. This was further confirmed in in vitro experiments in which viral RNA incubated with Rex and p30 increased complex formation, while RNAse had the opposite effect. Complexes of p30 and Rex also assembled onto cellular RNA, since the presence of RNAse inhibitor in absence of viral RNA was sufficient to stabilize p30-Rex interactions61. A Rex mutant in which six arginines involved in RNA binding have been mutated to lysines (RexLys) was shown to have the same cellular localization as the wildtype Rex, but to be selectively defective in RNA binding. Transient assays showed that RexLys failed to interact with p30 in the absence or in the presence of an HTLV-1 molecular clone, suggesting that Rex-RNA interactions may be required to recruit p30, or that p30 may interact within the RNA-binding site of Rex mutated in RexLys. Additional data suggested that p30, when bound onto RNA, efficiently recruited Rex even in the absence of an RXRE. Thus, Rex-RNA binding is not absolutely required, and consequently, p30 can interact within the Rex RNA-binding domain61. Studies aimed at understanding the specificity of p30 showed that Rex and p30 differentially associate onto viral mRNA. The p30-Rex complexes were significantly decreased in transient assays using a chimera RNA containing the RXRE only and no p30RE. These findings can be explained by the fact that Rex has a high affinity for its RXRE, and whenever Rex is bound to RNA, its p30 binding domain is no longer accessible, preventing p30-Rex protein complex formation. These results explain why gag/pol and env RNA are not subject to p30-mediated suppression72. In contrast, p30-Rex complexes increased when a chimera RNA containing both the RXRE and the p30RE was co-expressed along with p30 and Rex. However, it is likely that Rex is unable to multimerize and to recruit CRM1 in the absence of RXRE binding. Additional studies showed that an excess of Rex partially rescues tax/rex RNA from p30-mediated repression. Such a mechanism of regulation allows vigilant control of viral gene expression. The p30 reduces viral expression to prevent immune detection, but Rex guarantees low basal expression to produce a small amount of Tax essential for the early stages of T-cell transformation and to sustain expression of p30 (Fig. 4).

Figure 4
Rex and p30 govern the switch between virus latency and replication. When Rex is in excess, it binds onto the RXRE and exports incompletely spliced RNA to the cytoplasm. In contrast, when p30 is in excess, it inhibits Rex expression by binding to and ...


Human T-cell lymphotropic virus-1 has evolved multiple strategies to extend the lifespan of infected cells. This, in turn, allows accumulation of genetic mutations and, with time, disease progression. Because HTLV-1 is very immunogenic and has low variability, reducing its expression is key to virus maintenance in vivo. It is no surprise that HTLV-1 has evolved numerous strategies to limit its own expression. Tax is a potent transcriptional activator and very immunogenic. Hence, Tax expression needs to be tightly controlled. Tax is generally toxic, inducing multiple cell-cycle defects and apoptosis, in cells that have not yet acquired tolerance. Following initial infection, only cells with low Tax expression are able to survive. Thus, a natural cycle exists for selection of cells with low Tax expression. The HTLV-1 p12 has been shown to reduce major histocompatibility complex class I surface expression and decrease CTL recognition of infected cells. In addition, p30 limits tax/rex RNA export and thereby Tax expression75. Surprisingly, p30 protein also affects the toll-like receptor-4 signaling pathway, suggesting that HTLV-1 subverts a component of the host innate immunity. Recently, several studies have highlighted the role of HBZ in suppression of Tax expression.


this work was supported by the National Cancer Institute (grant RO1 AI 058944) to C.N.


1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481–92. [PubMed]
2. Poiesz B, Ruscetti F, Gazdar A, Bunn P, Minna J, Gallo R. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415–19. [PubMed]
3. Poiesz B, Ruscetti F, Mier J, Woods A, Gallo R. T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci USA. 1980;77:6815–19. [PubMed]
4. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031–5. [PubMed]
5. Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukemia. Lancet Oncol. 2004;5:664–72. [PubMed]
6. Gessain A, Barin F, Vernant J, et al. Antibodies to HTLV-1 in patients with tropical spastic paraparesis. Lancet. 1985;2:407–10. [PubMed]
7. Osame M, Usuku K, Izumo S, et al. HTLV-1 associated myelopathy, a new clinical entity. Lancet. 1986;1:1031–2. [PubMed]
8. Nicot C. Current views in HTLV-1-associated adult T-cell leukemia/lymphoma. Am J Hematol. 2005;78:232–9. [PubMed]
9. Franchini G, Nicot C, Johnson J. Seizing of T-cells by HTLV-1. Adv Cancer Res. 2003;89:69–132. [PubMed]
10. Bangham C, Osame M. Cellular immune response to HTLV-1. Oncogene. 2005;24:6035–46. [PubMed]
11. Takenouchi N, Yao K, Jacobson S. Immunopathogenesis of HTLV-1 associated neurologic disease: molecular, histopathologic, and immunologic approaches. Front Biosci. 2004;9:2527–39. [PubMed]
12. Koralnik I, Gessain A, Klotman M, Lo M, Berneman Z, Franchini G. Protein isoforms encoded by the pX region of HTLV-1. Proc Natl Acad Sci USA. 1992;89:8813–17. [PubMed]
13. Ciminale V, Pavlakis G, Derse D, Cunningham C, Felber B. Complex splicing in the HTLV family of retroviruses: novel mRNAs and proteins produced by HTLV-1. J Virol. 1992;66:1737–45. [PMC free article] [PubMed]
14. Gitlin S, Dittmer J, Shin R, Brady J. Transcriptional activation of the HTLV-1 long terminal repeat by functional interaction of Tax1 and Ets1. J Virol. 1993;67:7307–16. [PMC free article] [PubMed]
15. Kashanchi F, Brady J. Transcriptional and post-transcriptional gene regulation of HTLV-1. Oncogene. 2005;24:5938–51. [PubMed]
16. Younis I, Green P. The HTLV Rex protein. Front Biosci. 2005;10:431–45. [PMC free article] [PubMed]
17. Mesnard J, Barbeau B, Devaux C. HBZ, a new important player in the Mystery of adult T-cell leukemia. Blood. 2006;108:3979–82. [PubMed]
18. Jeong S, Lu H, Cho W, Park H, Pise-Masison C, Brady J. Coactivatorassociated arginine methyltransferase 1 enhances transcriptional activity of the HTLV-1 long terminal repeat through direct interaction with Tax. J Virol. 2006;80:10036–44. [PMC free article] [PubMed]
19. Siu Y, Chin K, Siu K, Yee Wai C, Jeang K, Jin D. TORC1 and TORC2 co-activators are required for tax activation of the HTLV-1 long terminal repeats. J Virol. 2006;80:7052–9. [PMC free article] [PubMed]
20. Koga H, Ohshima T, Shimotohno K. Enhanced activation of tax-dependent transcription of HTLV-1 long terminal repeat by TORC3. J Biol Chem. 2004;279:52978–83. [PubMed]
21. Jiang H, Lu H, Schiltz R, et al. PCAF interacts with tax and stimulates tax transactivation in a histone acetyltransferase-independent manner. Mol Cell Biol. 1999;19:8136–45. [PMC free article] [PubMed]
22. Harrod R, Tang Y, Nicot C, et al. An exposed KID-like domain in HTLV-1 Tax is responsible for the recruitment of coactivators CBP/p300. Mol Cell Biol. 1998;18:5052–61. [PMC free article] [PubMed]
23. Giebler H, Loring J, Van Orden K, et al. Anchoring of CREB binding protein to the HTLV-1 promoter: a molecular mechanism of Tax transactivation. Mol Cell Biol. 1997;17:5156–64. [PMC free article] [PubMed]
24. Taylor J, Nicot C. HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches. Apoptosis. 2008;13:733–47. [PMC free article] [PubMed]
25. Gatza M, Watt J, Marriott S. Cellular transformation by the HTLV-1 Tax protein, a jack-of-all-trades. Oncogene. 2003;22:5141–9. [PubMed]
26. Yamada Y, Kamihira S. Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma. Leuk Lymphoma. 2005;46:1553–9. [PubMed]
27. Marriott S, Semmes O. Impact of HTLV-1 Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene. 2005;24:5986–95. [PubMed]
28. Bellon M, Nicot C. Regulation of telomerase and telomeres: human tumor viruses take control. J Natl Cancer Inst. 2008;100:98–108. [PubMed]
29. Seiki M, Inoue J, Hidaka M, Yoshida M. Two cis-acting elements responsible for posttranscriptional trans-regulation of gene expression of HTLV-1. Proc Natl Acad Sci USA. 1988;85:7124–8. [PubMed]
30. Wen W, Meinkoth J, Tsien R, Taylor S. Identification of a signal for rapid export of proteins from the nucleus. Cell. 1995;82:463–73. [PubMed]
31. Bogerd H, Fridell R, Benson R, Hua J, Cullen B. Protein sequence requirements for function of the HTLV-1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay. Mol Cell Biol. 1996;16:4207–14. [PMC free article] [PubMed]
32. Kim F, Beeche A, Hunter J, Chin D, Hope T. Characterization of the nuclear export signal of HTLV-1 Rex reveals that nuclear export is mediated by position-variable hydrophobic interactions. Mol Cell Biol. 1996;16:5147–55. [PMC free article] [PubMed]
33. Palmeri D, Malim M. The HTLV-1 posttranscriptional trans-activator Rex Contains a nuclear export signal. J Virol. 1996;70:6442–5. [PMC free article] [PubMed]
34. Ossareh-Nazari B, Bachelerie F, Dargemont C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science. 1997;278:141–4. [PubMed]
35. Fornerod M, Ohno M, Yoshida M, Mattaj I. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell. 1997;90:1051–60. [PubMed]
36. Stade K, Ford C, Guthrie C, Weis K. Exportin 1 (Crm1p) is an essential Nuclear export factor. Cell. 1997;90:1041–50. [PubMed]
37. Bischoff F, Ponstingl H. Catalysis of guanine nucleotide exchange on Ran by the mitotic regulator RCC1. Nature. 1991;354:80–2. [PubMed]
38. Hakata Y, Umemoto T, Matsushita S, Shida H. Involvement of human CRM1 (exportin 1) in the export and multimerization of the Rex protein of HTLV-1. J Virol. 1998;72:6602–7. [PMC free article] [PubMed]
39. Englmeier L, Fornerod M, Bischoff F, Petosa C, Mattaj I, Kutay U. RanBP3 influences interactions between CRM1 and its nuclear protein export substrates. EMBO Rep. 2001;2:926–32. [PubMed]
40. Malim M, Cullen B. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell. 1991;65:241–8. [PubMed]
41. Bogerd H, Greene W. Dominant negative mutants of HTLV-1 Rex and HIV-1 Rev fail to multimerize in vivo. J Virol. 1993;67:2496–502. [PMC free article] [PubMed]
42. Heger P, Rosorius O, Koch C, Casari G, Grassmann R, Hauber J. Multimer formation is not essential for nuclear export of HTLV-1 Rex transactivator protein. J Virol. 1998;72:8659–68. [PMC free article] [PubMed]
43. Koya Y, Ohashi T, Kato H, et al. Establishment of a seronegative HTLV- 1 carrier state in rats inoculated with a syngeneic HTLV-1-immortalized T-cell line preferentially expressing Tax. J Virol. 1999;73:6436–43. [PMC free article] [PubMed]
44. Hakata Y, Yamada M, Shida H. Rat CRM1 is responsible for the poor activity of HTLV-1 Rex protein in rat cells. J Virol. 2001;75:11515–25. [PMC free article] [PubMed]
45. Takayanagi R, Ohashi T, Yamashita E, et al. Enhanced replication of HTLV-1 in T-cells from transgenic rats expressing human CRM1 that is regulated in a natural manner. J Virol. 2007;81:5908–18. [PMC free article] [PubMed]
46. Hakata Y, Yamada M, Shida H. A multifunctional domain in human CRM1 (exportin 1) mediates RanBP3 binding and multimerization of HTLV-1 Rex protein. Mol Cell Biol. 2003;23:8751–61. [PMC free article] [PubMed]
47. Katahira J, Ishizaki T, Sakai H, Adachi A, Yamamoto K, Shida H. Effects of translation initiation factor eIF-5A on the functioning of HTLV-1 Rex and HIV Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding. J Virol. 1995;69:3125–33. [PMC free article] [PubMed]
48. Grone M, Hoffmann E, Berchtold S, Cullen R, Grassmann R. A single stem-loop structure within the HTLV-1 Rex response element is sufficient to mediate Rex activity in vivo. Virology. 1994;204:144–52. [PubMed]
49. Hanly S, Rimsky L, Malim M, et al. Comparative analysis of the HTLV-1 Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Genes Dev. 1989;3:1534–44. [PubMed]
50. Ahmed Y, Hanly S, Malim M, Cullen B, Greene W. Structure-function analyses of the HTLV-1 Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. Genes Dev. 1990;4:1014–22. [PubMed]
51. Bogerd H, Huckaby G, Ahmed Y, Hanly S, Greene W. The HTLV-1 Rex transactivator binds directly to the HTLV-1 Rex and the HIV-1 Rev RNA response elements. Proc Natl Acad Sci USA. 1991;88:5704–8. [PubMed]
52. Bogerd H, Tiley L, Cullen B. Specific binding of the HTLV-1 Rex protein to a short RNA sequence located within the Rex-response element. J Virol. 1992;66:7572–5. [PMC free article] [PubMed]
53. Rimsky L, Hauber J, Dukovich M, et al. Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature. 1988;335:738–40. [PubMed]
54. Unge T, Solomin L, Mellini M, Derse D, Felber B, Pavlakis G. The Rex Regulatory protein of HTLV-1 binds specifically to its target site within the viral RNA. Proc Natl Acad Sci USA. 1991;88:7145–49. [PubMed]
55. Rimsky L, Dodon M, Dixon E, Greene W. Trans-dominant inactivation of HTLV-1 and HIV-1 gene expression by mutation of the HTLV-1 Rex transactivator. Nature. 1989;341:453–6. [PubMed]
56. Solomin L, Felber B, Pavlakis G. Different sites of interaction for Rev, Tev, and Rex proteins within the Rev-responsive element of HIV-1. J Virol. 1990;64:6010–17. [PMC free article] [PubMed]
57. Dodon M, Hamaia S, Martin J, Gazzolo L. Heterogeneous nuclear ribonucleoprotein A1 interferes with the binding of the HTLV-1 rex regulatory protein to its response element. J Biol Chem. 2002;277:18744–52. [PubMed]
58. Ahmed Y, Gilmartin G, Hanly S, Nevins J, Greene W. The HTLV-1 Rex response element mediates a novel form of mRNA polyadenylation. Cell. 1991;64:727–37. [PubMed]
59. Siomi H, Shida H, Nam S, Nosaka T, Maki M, Hatanaka M. Sequence requirements for nucleolar localization of HTLV-1 pX protein, which regulates viral RNA processing. Cell. 1988;55:197–209. [PubMed]
60. Adachi Y, Copeland T, Hatanaka M, Oroszlan S. Nucleolar targeting signal of Rex protein of HTLV-1 specifically binds to nucleolar shuttle protein B-23. J Biol Chem. 1993;268:13930–4. [PubMed]
61. Sinha-Datta U, Datta A, Ghorbel S, Dodon M, Nicot C. HTLV-1 rex and p30 interactions govern the switch between virus latency and replication. J Biol Chem. 2007;282:14608–15. [PubMed]
62. Grone M, Koch C, Grassmann R. The HTLV-1 Rex protein induces nuclear accumulation of unspliced viral RNA by avoiding intron excision and degradation. Virology. 1996;218:316–25. [PubMed]
63. Adachi Y, Nosaka T, Hatanaka M. Protein kinase inhibitor H-7 blocks accumulation of unspliced mRNA of HTLV-1. Biochem Biophys Res Commun. 1990;169:469–75. [PubMed]
64. Adachi Y, Copeland T, Takahashi C, et al. Phosphorylation of the Rex protein of HTLV-1. J Biol Chem. 1992;267:21977–81. [PubMed]
65. McGuire K, Curtiss V, Larson E, Haseltine W. Influence of HTLV-1 tax and rex on IL-2 gene expression. J Virol. 1993;67:1590–9. [PMC free article] [PubMed]
66. Kanamori H, Suzuki N, Siomi H, et al. HTLV-1 p27rex stabilizes human IL-2 receptor-α chain mRNA. EMBO J. 1990;9:4161–6. [PubMed]
67. White K, Nosaka T, Kanamori H, Hatanaka M, Honjo T. The nucleolar localization signal of the HTLV-1 protein p27rex is important for stabilization of IL-2 receptor-α subunit mRNA by p27rex. Biochem Biophys Res Commun. 1991;175:98–103. [PubMed]
68. Kanamori H, Kodama T, Yazaki Y. The 5′ coding sequence of IL-2 receptor-α chain mRNA mediates mRNA stabilization by HTLV-1 Rex. Immunology. 1995;86:551–5. [PubMed]
69. Weil R, Levraud J, Dodon M, et al. Altered expression of tyrosine kinases of the Src and Syk families in HTLV-1-infected T-cell lines. J Virol. 1999;73:3709–17. [PMC free article] [PubMed]
70. Cooke M, Abraham K, Forbush K, Perlmutter R. Regulation of T-cell receptor signaling by a src family protein-tyrosine kinase (p59fyn) Cell. 1991;65:281–91. [PubMed]
71. Valentin H, Hamaia S, Konig S, Gazzolo L. Vascular cell adhesion molecule-1 induced by HTLV-1 Tax protein in T-cells stimulates proliferation of human T-lymphocytes. J Gen Virol. 2001;82:831–5. [PubMed]
72. Nicot C, Dundr M, Johnson J, et al. HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med. 2004;10:197–201. [PubMed]
73. Albrecht B, Lairmore M. Critical role of HTLV-1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev. 2002;66:396–406. [PMC free article] [PubMed]
74. Nicot C, Harrod R, Ciminale V, Franchini G. HTLV-1 nonstructural genes and their functions. Oncogene. 2005;24:6026–34. [PubMed]
75. D’Agostino D, Silic-Benussi M, Hiraragi H, Lairmore M, Ciminale V. The HTLV-1 p13II protein: effects on mitochondrial function and cell growth. Cell Death Differ. 2005;12(Suppl 1):905–15. [PMC free article] [PubMed]
76. Derse D, Mikovits J, Ruscetti F. X-I and X-II open reading frames of HTLV-1 are not required for virus replication or for immortalization of primary T-cells in vitro. Virology. 1997;237:123–8. [PubMed]
77. Robek M, Wong F, Ratner L. HTLV-1 pX-I and pX-II open reading frames are dispensable for the immortalization of primary lymphocytes. J Virol. 1998;72:4458–62. [PMC free article] [PubMed]
78. Princler G, Julias J, Hughes S, Derse D. Roles of viral and cellular proteins in the expression of alternatively spliced HTLV-1 pX mRNAs. Virology. 2003;317:136–45. [PubMed]
79. Cereseto A, Berneman Z, Koralnik I, Vaughn J, Franchini G, Klotman M. Differential expression of alternatively spliced pX mRNAs in HTLV-I-infected cell lines. Leukemia. 1997;11:866–70. [PubMed]
80. Berneman Z, Gartenhaus R, Reitz M, et al. Expression of alternatively spliced HTLV-1 pX mRNA in infected cell lines and in primary uncultured cells from patients with ATLL and healthy carriers. Proc Natl Acad Sci USA. 1992;89:3005–9. [PubMed]
81. Dekaban G, Peters A, Mulloy J, et al. The HTLV-1 orfI protein is recognized by serum antibodies from naturally infected humans and experimentally infected rabbits. Virology. 2000;274:86–93. [PubMed]
82. Pique C, Ureta-Vidal A, Gessain A, et al. Evidence for the chronic in vivo production of HTLV-1 Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides. J Exp Med. 2000;191:567–72. [PMC free article] [PubMed]
83. Hiraragi H, Kim S, Phipps A, et al. HTLV-1 mitochondrion-localizing protein p13(II) is required for viral infectivity in vivo. J Virol. 2006;80:3469–76. [PMC free article] [PubMed]
84. Silverman L, Phipps A, Montgomery A, Ratner L, Lairmore M. HTLV-1 open reading frame II-encoded p30II is required for in vivo replication: evidence of in vivo reversion. J Virol. 2004;78:3837–45. [PMC free article] [PubMed]
85. Lairmore M, Albrecht B, D’Souza C, et al. In vitro and in vivo functional analysis of HTLV-1 pX open reading frames I and II. AIDS Res Hum Retroviruses. 2000;16:1757–64. [PubMed]
86. Bartoe J, Albrecht B, Collins N, et al. Functional role of pX open reading frame II of HTLV-1 in maintenance of viral loads in vivo. J Virol. 2000;74:1094–100. [PMC free article] [PubMed]
87. Collins N, Newbound G, Albrecht B, Beard J, Ratner L, Lairmore M. Selective ablation of HTLV-1 p12I reduces viral infectivity in vivo. Blood. 1998;91:4701–7. [PubMed]
88. Michael B, Nair A, Hiraragi H, et al. HTLV-1 p30II alters cellular gene expression to selectively enhance signaling pathways that activate T lymphocytes. Retrovirology. 2004;1:39. [PMC free article] [PubMed]
89. Younis I, Khair L, Dundr M, Lairmore M, Franchini G, Green P. Repression of HTLV type 1 and type 2 replication by a viral mRNA-encoded posttranscriptional regulator. J Virol. 2004;78:11077–83. [PMC free article] [PubMed]
90. Dundr M, Misteli T. Functional architecture in the cell nucleus. Biochem J. 2001;356:297–310. [PubMed]
91. Moroianu J, Riordan J. Identification of the nucleolar targeting signal of human angiogenin. Biochem Biophys Res Commun. 1994;203:1765–72. [PubMed]
92. Creancier L, Prats H, Zanibellato C, Amalric F, Bugler B. Determination of the functional domains involved in nucleolar targeting of nucleolin. Mol Biol Cell. 1993;4:1239–50. [PMC free article] [PubMed]
93. Ghorbel S, Sinha-Datta U, Dundr M, Brown M, Franchini G, Nicot C. HTLV-1 p30 nuclear/nucleolar retention is mediated through interactions with RNA and a constituent of the 60 S ribosomal subunit. J Biol Chem. 2006;281:37150–8. [PubMed]
94. Boisvert F, van Koningsbruggen S, Navascues J, Lamond A. The multifunctional nucleolus. Nat Rev Mol Cell Biol. 2007;8:574–85. [PubMed]
95. Hiscox J. RNA viruses: hijacking the dynamic nucleolus. Nat Rev Microbiol. 2007;5:119–27. [PubMed]
96. Hiscox J. The nucleolus–a gateway to viral infection? Arch Virol. 2002;147:1077–89. [PubMed]
97. Dhar D, Mapa K, Pudi R, Srinivasan P, Bodhinathan K, Das S. Human ribosomal protein L18a interacts with HCV internal ribosome entry site. Arch Virol. 2006;151:509–24. [PubMed]
98. Ji H, Fraser C, Yu Y, Leary J, Doudna J. Coordinated assembly of human translation initiation complexes by the HCV internal ribosome entry site RNA. Proc Natl Acad Sci USA. 2004;101:16990–5. [PubMed]
99. Haas M, Geldreich A, Bureau M, et al. The open reading frame VI product of Cauliflower mosaic virus is a nucleocytoplasmic protein: its N terminus mediates its nuclear export and formation of electron-dense viroplasms. Plant Cell. 2005;17:927–43. [PubMed]
100. Bureau M, Leh V, Haas M, et al. P6 protein of Cauliflower mosaic virus, a translation reinitiator, interacts with ribosomal protein L13 from Arabidopsis thaliana. J Gen Virol. 2004;85:3765–75. [PubMed]
101. Leh V, Yot P, Keller M. The cauliflower mosaic virus translational transactivator interacts with the 60S ribosomal subunit protein L18 of Arabidopsis thaliana. Virology. 2000;266:1–7. [PubMed]
102. Dundr M, Leno G, Hammarskjold M, et al. The roles of nucleolar structure and function in the subcellular location of the HIV-1 Rev protein. J Cell Sci. 1995;108:2811–23. [PubMed]
103. Kubota S, Hatanaka M, Pomerantz R. Nucleocytoplasmic redistribution of the HTLV-1 Rex protein: alterations by co-expression of the HTLV-1 p21x protein. Virology. 1996;220:502–7. [PubMed]